Antimicrobial Activity of Colistin Against Contemporary (2015-2017)P. aeruginosaandA. baumanniiIsolates From a Chinese Surveillance Program

被引:4
作者
Zhang, Hui [1 ]
Zhang, Ge [1 ]
Zhang, Jingjia [1 ]
Duan, Simeng [1 ]
Kang, Yue [2 ]
Yang, Qiwen [1 ]
Xu, Yingchun [1 ]
机构
[1] Chinese Acad Med Sci, Dept Clin Lab, Peking Union Med Coll Hosp, Peking Union Med Coll, Beijing, Peoples R China
[2] MSD China, MRL Global Med Affairs, Shanghai, Peoples R China
关键词
Pseudomonas aeruginosa; Acinetobacter baumannii; carbapenem; colistin; RTI; IAI; UTI; RESISTANT ACINETOBACTER-BAUMANNII; MULTIDRUG-RESISTANT; PSEUDOMONAS-AERUGINOSA; DRUG-RESISTANCE; RISK-FACTORS; PNEUMONIA; EPIDEMIOLOGY; CARBAPENEMS; INFECTIONS; PREVALENCE;
D O I
10.3389/fmicb.2020.01966
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Objective To investigate the incidence and susceptibilities of non-fermenting bacteria isolates from Chinese respiratory (RTI), intra-abdominal (IAI) and urinary tract (UTI) infections to antimicrobial agents between 2015 and 2017. Methods In total, 3,246 non-fermentative bacteria were collected from 21 hospitals and 9 hospital departments across 7 regions of China. A central testing laboratory was employed to determine antimicrobial susceptibilities using appropriate standards of interpretation. Results The majority of the isolates wereAcinetobacter baumannii(n= 1,360, 41.9%) andPseudomonas aeruginosa(n= 1,341, 41.3%). Overall multidrug resistance (MDR) and carbapenem resistance (CR) rates ofAcinetobacter baumanniiwere 80.1 and 78.7% with MDR and CR rates in RTIs, IAIs, and UTIs of 82.0 and 81.0%, 82.6 and 81.0% as well as 53.1 and 46.9%. Overall MDR and CR rates ofPseudomonas aeruginosaisolates were 36.2 and 38.9% with 41.8 and 44.3%, 29.3 and 36.1% as well as 24.2 and 20.2% MDR and CR rates in RTIs, IAIs, and UTIs. Overall susceptibility rates to imipenem, meropenem, amikacin, ciprofloxacin, cefepime and piperacillin-tazobactam were 21.1, 21.3, 33.0, 18.4, 19.2, and 19.6% forAcinetobacter baumanniiand 56.5, 58.5, 88.4, 63.1, 63.1, and 55.63% forPseudomonas aeruginosaisolates, whereas for colistin they were 95.7 and 94.6%, respectively. In all departments and regions of China, susceptibility rates ofPseudomonas aeruginosaandAcinetobacter baumanniiisolates to colistin were constantly above 80%. Conclusion Due to the high MDR and CR rates forPseudomonas aeruginosaandAcinetobacter baumannii, isolates obtained from RTIs, IAIs, and UTIs only maintained high susceptibility rates to colistin between 2015 and 2017.
引用
收藏
页数:11
相关论文
共 45 条
  • [1] [Anonymous], 2012, CHIN MED J
  • [2] [Anonymous], 2018, DET REP COL RES
  • [3] [Anonymous], 2016, CLSI
  • [4] Colistin-resistant Pseudomonas aeruginosa clinical strains with defective biofilm formation
    Azimi, Leila
    Lari, Abdolaziz Rastegar
    [J]. GMS HYGIENE AND INFECTION CONTROL, 2019, 14
  • [5] The clinical significance of pneumonia in patients with respiratory specimens harbouring multidrug-resistant Pseudomonas aeruginosa: a 5-year retrospective study following 5667 patients in four general ICUs
    Borgatta, B.
    Gattarello, S.
    Mazo, C. A.
    Imbiscuso, A. T.
    Larrosa, M. N.
    Lujan, M.
    Rello, J.
    [J]. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2017, 36 (11) : 2155 - 2163
  • [6] Epidemiology and carbapenem resistance mechanisms of carbapenem-non-susceptible Pseudomonas aeruginosa collected during 2009-11 in 14 European and Mediterranean countries
    Castanheira, Mariana
    Deshpande, Lalitagauri M.
    Costello, Andrew
    Davies, Todd A.
    Jones, Ronald N.
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2014, 69 (07) : 1804 - 1814
  • [7] Independent Emergence of Colistin-Resistant Enterobacteriaceae Clinical Isolates without Colistin Treatment
    Chen, Shudan
    Hu, Fupin
    Zhang, Xuelian
    Xu, Xiaogang
    Liu, Yang
    Zhu, Demei
    Wang, Honghai
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 2011, 49 (11) : 4022 - 4023
  • [8] Epidemiology of Bloodstream Infections Caused by Acinetobacter baumannii and Impact of Drug Resistance to both Carbapenems and Ampicillin-Sulbactam on Clinical Outcomes
    Chopra, Teena
    Marchaim, Dror
    Awali, Reda A.
    Krishna, Amar
    Johnson, Paul
    Tansek, Ryan
    Chaudary, Khawar
    Lephart, Paul
    Slim, Jessica
    Hothi, Jatinder
    Ahmed, Harris
    Pogue, Jason M.
    Zhao, Jing J.
    Kaye, Keith S.
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2013, 57 (12) : 6270 - 6275
  • [9] Colistin-Resistant Acinetobacter baumannii Clinical Strains with Deficient Biofilm Formation
    Dafopoulou, Konstantina
    Xavier, Basil Britto
    Hotterbeekx, An
    Janssens, Lore
    Lammens, Christine
    De, Emmanuelle
    Goossens, Herman
    Tsakris, Athanasios
    Malhotra-Kumar, Surbhi
    Pournaras, Spyros
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2016, 60 (03) : 1892 - 1895
  • [10] Understanding resistance in Pseudomonas
    Dimopoulos, George
    Akova, Murat
    Rello, Jordi
    Poulakou, Garyphalia
    [J]. INTENSIVE CARE MEDICINE, 2020, 46 (02) : 350 - 352